Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. Issue 7 (3rd May 2021)

Record Type:: Journal Article
Title:: Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. Issue 7 (3rd May 2021)
Main Title:: Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21
Authors:: Kimmich, Christoph R.
Terzer, Tobias
Benner, Axel
Hansen, Timon
Carpinteiro, Alexander
Dittrich, Tobias
Veelken, Kaya
Jauch, Anna
Huhn, Stefanie
Basset, Marco
Goldschmidt, Hartmut
Müller‐Tidow, Carsten
Schönland, Stefan O.
Hegenbart, Ute
Abstract:
Is Part Of:: American journal of hematology. Volume 96:Issue 7(2021)
Journal:: American journal of hematology
Issue:: Volume 96:Issue 7(2021)
Issue Display:: Volume 96, Issue 7 (2021)
Year:: 2021
Volume:: 96
Issue:: 7
Issue Sort Value:: 2021-0096-0007-0000
Page Start:: E253
Page End:: E257
Publication Date:: 2021-05-03
Subjects:: Hematology -- Periodicals
616.15
Journal URLs:: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-8652 ↗
http://onlinelibrary.wiley.com/ ↗
DOI:: 10.1002/ajh.26191 ↗
Languages:: English
ISSNs:: 0361-8609
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 0824.800000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 24650.xml